c102594.htm - Generated by SEC Publisher for SEC Filing

 

 


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

APRIL 27, 2010

________________

 

        NOVO NORDISK A/S       
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 


 

logo.gif

Company Announcement

26 April 2010

Novo Nordisk A/S – Share repurchase programme

On 2 February 2010 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk A/S has repurchased B shares for an amount of DKK 2.0 billion in the period from 2 February 2010 to 26 April 2010. Consequently, the programme has been concluded on 26 April 2010.

Since the announcement as of 19 April 2010, the following transactions have been made under the programme:

 

Number of

shares

Average

purchase price

Transaction value,

DKK

Accumulated, last

announcement

4,395,000

 

1,787,917,268

19 April 2010

50,000

445.7600

22,288,000

20 April  2010

70,000

450.6500

31,545,500

21 April  2010

90,000

453.8810

40,849,290

22 April  2010

145,000

450.2028

65,279,406

23 April  2010

70,000

448.1360

31,369,520

26 April  2010

45,000

451.4500

20,540,975

Accumulated under

the programme

4,865,500

 

1,999,789,959

With the transactions stated above, Novo Nordisk owns a total of 35,136,798 treasury shares, corresponding to 5.7% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Company Announcement no 22 / 2010

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

 

 

Media:

Investors:

 

Elin K Hansen

Tel: (+45) 4442 3450

ekh@novonordisk.com

Klaus Bülow Davidsen

Tel: (+45) 4442 3176

klda@novonordisk.com

 

 

 

 

Kasper Roseeuw Poulsen

Tel: (+45) 4442 4471

krop@novonordisk.com

 

In North America:

Sean Clements

Tel: (+1) 609 514 8316

secl@novonordisk.com

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

hrmm@novonordisk.com

 

Company Announcement no 22 / 2010

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: APRIL 27, 2010

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer